Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L L Miller

Showing results (161-170 of 179) with videos related to

Pageof 18
Sort By:
Blood|March 27, 2001
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinomaJ E Janik, L L Miller, E L Korn, et al.
The New England Journal of Medicine|September 28, 2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupL B Saltz, J V Cox, C Blanke, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
Alternative dosing schedules for irinotecanM L Rothenberg, J G Kuhn, L J Schaaf, et al.
The New England Journal of Medicine|June 19, 1997
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropeniaL C Hartmann, L K Tschetter, T M Habermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancyH C Pitot, R M Goldberg, J M Reid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumorsL B Saltz, D Spriggs, L J Schaaf, et al.
Physical Review Letters|February 9, 2005
Missing quasiparticles and the chemical potential puzzle in the doping evolution of the cuprate superconductorsK M Shen, F Ronning, D H Lu, et al.
Clinical Immunology (Orlando, Fla.)|December 22, 1999
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patientsJ E Janik, L L Miller, W C Kopp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study GroupM Kaufmann, E Bajetta, L Y Dirix, et al.
Clinical Breast Cancer|April 24, 2002
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized studyM Kaufmann, E Bajetta, L Y Dirix, et al.
Pageof 18

Showing results (161-170 of 179) with videos related to

Sort By:
Pageof 18
Blood|March 27, 2001
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinomaJ E Janik, L L Miller, E L Korn, et al.
The New England Journal of Medicine|September 28, 2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupL B Saltz, J V Cox, C Blanke, et al.
Oncology (Williston Park, N.Y.)|September 3, 1998
Alternative dosing schedules for irinotecanM L Rothenberg, J G Kuhn, L J Schaaf, et al.
The New England Journal of Medicine|June 19, 1997
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropeniaL C Hartmann, L K Tschetter, T M Habermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2000
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancyH C Pitot, R M Goldberg, J M Reid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumorsL B Saltz, D Spriggs, L J Schaaf, et al.
Physical Review Letters|February 9, 2005
Missing quasiparticles and the chemical potential puzzle in the doping evolution of the cuprate superconductorsK M Shen, F Ronning, D H Lu, et al.
Clinical Immunology (Orlando, Fla.)|December 22, 1999
Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patientsJ E Janik, L L Miller, W C Kopp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study GroupM Kaufmann, E Bajetta, L Y Dirix, et al.
Clinical Breast Cancer|April 24, 2002
Exemestane improves survival in metastatic breast cancer: results of a phase III randomized studyM Kaufmann, E Bajetta, L Y Dirix, et al.
Pageof 18